The February 2022 outbreak of Japanese encephalitis virus in Australia spurred action by animal and public health officials around the world. In the US, the pork industry began monitoring Australia’s situation and response, ramping up prevention and preparedness activities immediately. The Swine Health Information Center, along with industry partners, compiled a comprehensive list of research gaps to facilitate next steps in the ongoing efforts towards reducing the risk of JEV introduction and spread, understanding JEV’s impact on production, and investigating how on-farm factors influence JEV transmission.
An October 2022 JEV symposium co-sponsored by SHIC helped to inform the research gap identification effort, with needs broken into three areas of focus: immediate preparation response, intermediate response, and longer-term response. Review the full list of priorities here.
Immediate preparation/response
- Production loss. Investigate trade implications of a JEV incursion into the US; estimate the potential economic losses to the US pork industry due to production losses on sow farms, disrupted domestic and international markets, and trade restrictions if JEV is introduced.
- Epidemiology. Investigate the mechanism of JEV spread through a production site, defining the risks or epidemiological factors, including vector-free transmission, playing a role in the extent of spread and variation of clinical signs within a litter and across litters. Goals include identifying mitigation strategies to minimize JEV impact on farm production.
- Diagnostics. Design novel, or confirm current, diagnostic assays for JEV (PCR, antibody) at US veterinary diagnostic laboratories can distinguish between other flaviviruses in the US (West Nile virus, St Louis encephalitis virus) and will detect all five genotypes (I-V) of JEV.
- Eradication. Model spatiotemporal spread of JEV post-incursion to identify mitigation strategies for biocontainment and rapid eradication from the US.
- Communication. Determine the most effective consumer and producer messaging on JEV being a "mosquito disease," with the goal of minimizing negative effects on pork production and consumption while maximizing safety and protection of swine personnel in the event of JEV incursion.
Intermediate response
- Surveillance. Investigate surveillance targets (species, high risk locations in US, sample types) and diagnostic assays (PCR, antibody) to develop an effective surveillance plan for earliest detection of a JEV incursion into the US.
- Compatible cases. Investigate syndromic surveillance for case compatible VDL submissions in the US of reproductive disease from sow farms (abortions, mummified fetuses, stillborns, neonatal tremors) to define the annual or seasonal number of compatible cases, including the percent of cases in which no definitive diagnosis is determined.
- Challenge model. Develop experimental challenge models for JEV to interrogate interventions and their effect on clinical disease severity, pathogenesis in pregnant sows, transmission rates, virus replication, and prevalence within and across litters.
Longer term response
- Vaccines. Develop vaccine candidates for use in US commercial swine, to minimize production losses if JEV is introduced, that could be deployed post-outbreak and would allow differentiation of vaccinated from infected animals.
- Cross-protection. Determine the extent of JEV cross-protection that is present in US commercial swine after exposure to other flaviviruses (WNV, SLEV) endemic to the US.
- Mosquito control. Investigate effective mosquito control measures for swine farms in the US, including recommendations based on site design, ventilation type, and manure storage.
- Vectors. Investigate and characterize the competence of potential vector host species in the US for JEV, including their geographic proximity to feral and commercial swine populations, and propensity to feed on pigs or ardeid birds.
- Wildlife. Define the risk and mitigation of known wildlife hosts, such as feral swine and ardeid birds, in the role of JEV introduction and spread to commercial swine in the US.
- Novel hosts. Investigate and characterize the competence of novel vertebrate host species (non-ardeids and non-swine) in the US to act as amplifying or dead-end hosts of JEV, including their geographic distribution and proximity to commercial or feral swine.
- Sequencing. Investigate the molecular pathogenesis differences between genotype 4 and historical JEV genotypes, including an estimation of virulence factors based on whole genome sequencing.
SHIC is working with industry, university, and federal partners to address these research needs and enhance the ability of the US swine industry to prevent, prepare, and respond to JEV if introduced. As part of this process, SHIC is in communication with Australian veterinarians, producers, and researchers to discuss opportunities for JEV collaboration.
This list of research priorities builds on SHIC’s currently funded JEV preparedness efforts, including an updated JEV entry and establishment risk assessment, a comprehensive JEV literature review, and a JEV Information Sharing Network website. This new website will be a JEV information resource designed to answer the pork industry’s immediate questions and needs if JEV is introduced into the US. As research efforts progress, results will be shared by SHIC and posted on the SHIC website as soon as they become available.
SHIC, launched by the National Pork Board in 2015 solely with Pork Checkoff funding, continues to focus efforts on prevention, preparedness, and response to novel and emerging swine disease for the benefit of US swine health. As a conduit of information and research, SHIC encourages sharing of its publications and research. Forward, reprint, and quote SHIC material freely. SHIC is funded by America’s pork producers to fulfill its mission to protect and enhance the health of the US swine herd. For more information, visit https://www.swinehealth.org/ or contact Dr. Paul Sundberg at psundberg@swinehealth.org